Search research articles

Related Concept Videos

Immune Response Against Viral Pathogens

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

An unexpected finding of large bowel obstruction from colonic diaphragm disease following prolonged use of indomethacin.

Journal of surgical case reports·2026

Same author

Violence and non-fatal injuries among Thai adolescents: National prevalence, and sex-stratified risk and protective factors.

Injury·2025

Same author

Accuracy of the modified Global Burden of Disease International Classification of Diseases coding methods for identifying sepsis: a prospective multicentre cohort study.

Critical care (London, England)·2025

Same author

Menstrual hygiene knowledge and practices among adolescent schoolgirls in flood-affected rural Bangladesh.

Reproductive health·2025

Same author

Prevalence and associated risk factors of anxiety-induced sleep disturbance: Sex-stratified comparison among school-going adolescents in Paraguay.

Sleep medicine·2025

Same author

Students' safety culture at tertiary level academic institutes in Bangladesh: A cross-sectional study.

Heliyon·2025

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Mar 2, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Alpha-interferon treatment in hepatitis B.

Aaron Shu Jeng Woo¹, Raymond Kwok¹, Taufique Ahmed¹

¹Division of Gastroenterology and Hepatology, Alexandra Health Khoo Teck Puat Hospital, Singapore.

Annals of Translational Medicine

|May 9, 2017

Summary

Pegylated interferon-alfa (PEG-IFN-α) offers finite treatment for chronic hepatitis B, with predictors for sustained response in HBeAg-positive patients. Combination therapy with nucleos(t)ide analogues shows promise for higher HBsAg loss, though cure remains elusive.

Keywords:

Hepatitis B combination therapy interferon therapy predictors of response sustained response

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

Related Experiment Videos

Last Updated: Mar 2, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

Area of Science:

Hepatology
Virology
Immunology

Background:

Pegylated interferon-alfa (PEG-IFN-α) is a primary treatment for chronic hepatitis B.
Compared to nucleos(t)ide analogues (NAs), PEG-IFN-α offers finite treatment duration and higher seroconversion rates but more adverse effects.
Predicting sustained off-treatment response is crucial for PEG-IFN-α therapy.

Purpose of the Study:

To evaluate predictors of sustained off-treatment response to PEG-IFN-α in chronic hepatitis B.
To assess the efficacy of combining PEG-IFN-α with nucleos(t)ide analogues (NAs).
To explore strategies for improving hepatitis B surface antigen (HBsAg) loss rates.

Main Methods:

Analysis of baseline factors (genotype, viral load, ALT, age, gender) for predicting response in HBeAg-positive patients.
Utilizing on-treatment quantitative HBsAg levels to identify treatment failures.
Reviewing studies on combination therapy of PEG-IFN-α with NAs, including tenofovir disoproxil fumarate (TDF).

Main Results:

Baseline factors predict sustained response in HBeAg-positive disease (genotype A/B, low viral load, high ALT, older age, female gender).
No reliable pre-treatment predictors exist for HBeAg-negative disease.
On-treatment HBsAg levels have high negative predictive value for long-term response failure.
Combination therapy (PEG-IFN-α + NAs, especially TDF) shows higher HBsAg loss rates than monotherapy across genotypes.

Conclusions:

Predictive baseline factors improve PEG-IFN-α treatment selection for HBeAg-positive chronic hepatitis B.
Combination therapy with NAs, particularly TDF, enhances HBsAg loss.
Despite advances, achieving a cure for chronic hepatitis B remains a challenge, necessitating further research into optimal combination or sequential regimens.